Abstracts tagged "anti-TNF therapy and randomized trials"

Abstract Number: 422 • 2019 ACR/ARP Annual Meeting
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Vibeke Strand¹, Pankaj Patel ², Naijun Chen ² and Elizabeth M Lesser ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago
Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
Abstract Number: 3195 • 2015 ACR/ARHP Annual Meeting
Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial
Jacob Sode^1,2,3, Sophine B. Krintel⁴, Anting L. Carlsen⁵, Merete Lund Hetland⁶, Julia Johansen^7,8, Kim Hørslev-Petersen⁹, Kristian Stengaard-Pedersen¹⁰, Peter Junker¹¹, Mikkel Østergaard^12,13, Niels H. H. Heegaard^14,15 and OPERA study group, ¹Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ²Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, ³Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ⁶The DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁷Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁸Departments of Medicine and Oncology, Copenhagen University Hospital at Herlev, Copenhagen, Denmark, ⁹Rheumatology, Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark, ¹⁰Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹²Rigshospitalet-Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, Glostrup, Denmark, ¹³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ¹⁴Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ¹⁵Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose: The variable response to anti-TNF therapy in patients with rheumatoid arthritis (RA) remains largely unexplained, and biomarkers for treatment response are scarce. We previously…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].